Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.

Property Value
dbo:abstract
  • Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism. (en)
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-13 00:12:57Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 56104174 (xsd:integer)
dbo:wikiPageLength
  • 2467 (xsd:integer)
dbo:wikiPageModified
  • 2017-12-21 16:18:27Z (xsd:date)
dbo:wikiPageOutDegree
  • 15 (xsd:integer)
dbo:wikiPageRevisionID
  • 816477363 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdfs:comment
  • Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism. (en)
rdfs:label
  • Leflutrozole (en)
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of